Browse > Article
http://dx.doi.org/10.22246/jikm.2018.39.5.973

Traditional Korean Medicine for Skin Toxic Side Effects from Afatinib in a Non-Small Cell Lung Cancer Patient: A Case Report  

Shim, So-hyun (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Seo, Hee-jeong (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Choi, Jin-yong (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Bae, Go-eun (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Seo, Hyung-bum (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Kim, So-yeon (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Han, Chang-woo (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Park, Seong-ha (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Yun, Young-ju (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Lee, In (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Kwon, Jung-nam (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Hong, Jin-woo (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Choi, Jun-yong (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Publication Information
The Journal of Internal Korean Medicine / v.39, no.5, 2018 , pp. 973-983 More about this Journal
Abstract
Objectives: We report a case of traditional Korean medicine (TKM) treatment for skin side effects after taking afatinib (Giotrif$^{(R)}$). Methods: A 62-year-old female who was diagnosed with non-small cell lung cancer stage 4 (T4N2M1b) and was on treatment with afatinib (29.56 mg/day for 4 months) complained of skin toxicity as a side effect. For 16 admission days, the patient was treated with acupuncture, moxibustion, and herbal medicine (oral decoction and external ointment). Results: Improvement of skin toxicity was measured by a numeric rating scale. In addition, Quality of life (QOL) was measured using EORTC Quality of Life Questionnaire, Core 30 (EORTC QLQ-C30) and EORTC Quality of Life Questionnaire, 13-item lung cancer-specific module (EORTC QLQ-LC13) Developed by the European Organization for Research and Treatment of Cancer (EORTC). Tumor size and carcinoembryonic antigen (CEA) were also examined during follow up. Conclusions: After a combined TKM treatment, skin toxicity symptoms and quality of life scales were significantly improved with no side effects. The tumor size was not changed on computed tomography during follow-up period. CEA levels were decreased.
Keywords
non-small cell lung carcinoma; epidermal growth factor receptor; afatinib; traditional Korean medicine; case report;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Kasymjanova G, Grossman M, Tran T, Jagoe RT, Cohen V, Pepe C, et al. The potential role for acupuncture in treating symptoms in patients with lung cancer:an observational longitudinal study. Curr Oncol 2013:20(3):152-7.   DOI
2 Stewart B, Wild CP. World Cancer Report. 2014.
3 Horn L, Lovly CM, Johnson DH. Neoplasms of the Lung. In : Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine, 19e. New York, NY: McGraw-Hill Education: 2015.
4 D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, et al. Distinct clinical course of EGFR-mutant resected lung cancers:results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol 2012:7(12):1815-22.   DOI
5 Lee DH, Srimuninnimit V, Cheng R, Wang X, Orlando M. Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned. Cancer Res Treat 2015:47(4):549-54.   DOI
6 Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013:31(27):3327-34.   DOI
7 Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, et al. Symptom control and quality of life in LUX-Lung 3:a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013:31(27):3342-50.   DOI
8 Park JW, Jun HJ, Cho CK, Lee YW. One Case Study of a Non Small Cell Lung Cancer Patient Experienc ing Gefitinib Adverse Effects Managed by Traditional Korean Medicine. J of Kor Traditional Oncology 2012:17(1):9-16.   DOI
9 Yun SJ, Lee JB, Kim KS, Kim YC. Cutaneous Adverse Reactions Induced by Gefitinib (Iressa) in Lung Cancer Patients. Tuberculosis and Respiratory Diseases. 2006:61(2):150-6.   DOI
10 Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean version of the EORTC QLQ-C30. Quality of Life Research 2004:13(4):863-8.   DOI
11 Kim KS, Jung TY, Yoo HS, Lee YW, Cho CK. Case Series of Advanced Non-small Cell Lung Cancer Patients Treated with Hang-Am-Plus. Korean J OrientInt Med 2009:30(4):893-900.
12 Lee HJ, Sim HS, Seo JK, Lee D, Sung HS. Cutaneous Adverse Reaction Associatied with Epidermal Growth Factor Receptor Inhibitor. Korean J Dermatol 2011:49(2):131-40.
13 Kim YH, Kim YT, Kim HK, Park IG, Wu HG, Song SY, et al. Lung cancer guideline. Korean Association for Lung Cancer 2010.
14 Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clinical lung cancer 2009:10(2):106-11.   DOI
15 Son JY, Choi GH, Yoo HJ, Kim HJ, Goo JW, Park MY, et al. One Clinical Case Report of Lung Cancer Patient with Dyspnea Prescribed Oriental Medicine. Korean J Orient Int Med 2009:30(1):233-40.
16 He W, Cheng M. Meta-analysis on effectiveness and safety of traditional Chinese medicine combined with first-generation EGF R-TKI in treating advanced non-small cell lung cancer. China Journal of Chinese Materia 2017:42(13):2591-8.
17 Zhang X, Zhao Y. TCM differentiation and treatment of non-small cell lung cancer targeted drug-related dermal toxicity. J Tradit Chin Med 2015:56(12):1065-6.
18 Jeon BH. Influence of the extract of RADIX ASTRAGALI on the cytotoxicity induced by the chemotherapeutic agents, mitomycion C. J Physiol & Pathol Korean Med 1998:12(1):55-9.
19 Seo SH, Choi MO. Glycyrrhizae Radix Suppresses Human TNF-${\alpha}$-induced Inflammation Via Blockade of p38 Activation in HaCaT Cells. J Kor Soc Cosm 2013:19(2):207-14.
20 Lee JY, Park HY, Yeom MH, Kim DH, Kim HK. The Protective Effects of Astragali Radix Against UV Induced Cellular Damage in Human Keratinocytes. Kor J Pharmacogn 2008:39(4):300-4.